title: Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
abstract: Comparison of the recurrence rates of soft tissue sarcomas treated by radiotherapy (14 patients) or radiotherapy and synchronous administration of razoxane (19 patients) has shown a statistically significant benefit for those patients treated by the combination. No increase in tissue reactions or adverse side-effects (apart from a readily reversible leukopenia) was observed. The implication is that razoxane acts as a well tolerated adjuvant for radiotherapy.
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011882:Radiotherapy, High-Energy; D011929:Razoxane / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D012075:Remission, Spontaneous; D012509:Sarcoma / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000628:therapy*
chemical_list: D010879:Piperazines; D011929:Razoxane